As shown in Figure 5H and Figure S28, whereas the tumor-bearing mice treated with PBS, RNP, and mockRNP/A1I2R2C18 complexes exhibited rapid growth of tumor volume, theperitumoral administration of RNP/A1I2R2C18 complexes could effectivelyinhibit tumor growth, suggesting the efficient genomic disruptionof mutant KRAS. 46 Therewas no significant body weight change for the mice treated with RNP/A1I2R2C18complexes, suggesting the safety profile of the treatment (Figure S29). The gene discussed is KRAS; the disease is neoplasm.